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Abstract
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Tauopathies are a class of neurodegenerative diseases associated with the pathological
aggregationof the tau protein in the human brain. The best known of these illnesses is Alzheimer's
disease (AD); a disease where the microtubule associated protein tau (MAPT) becomes
hyperphosphorylated (lowering its binding affinity to microtubules) and aggregates within neurons
in the form of neurofibrillary tangles (NFTs). In this paper we examine whether environmental
factors play a significant role in tau pathogenesis. Our studies were conducted in a double mutant
mouse model that expressed the human tau gene and lacked the gene for murine tau. The human
tau mouse model was tested for the transgene's ability to respond to an environmental toxicant.
Pups were developmentally exposed to lead (Pb) from postnatal day (PND) 1-20 with 0.2% Pb
acetate. Mice were then sacrificed at PND 20, 30, 40 and 60. Protein and mRNA levels for tau and
CDK5 as well as tau phosphorylation at Ser396 were determined. In addition, the potential role of
miRNA in tau expression was investigated by measuring levels of miR-34c, a miRNA that targets
the mRNA for human tau, at PND20 and 50. The expression of the human tau transgene was
altered by developmental exposure to Pb. This exposure also altered the expression of miR-34c.
Our findings are the first of their kind to test the responsiveness of the human tau gene to an
environmental toxicant and to examine an epigenetic mechanism that may be involved in the
regulation of this gene's expression.
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1. Introduction
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Tauopathies are a class of neurodegenerative diseases associated with the pathological
aggregation of the tau protein in the human brain. There are approximately thirty known
tauopathies, with different clinical, pathological and biological characteristics (CailletBoudin et al., 2015). Some tauopathies are considered familial and are related to precise
mutations of the tau gene, while others are sporadic in nature with no direct genetic links.
Perhaps the best-known tauopathy is Alzheimer's disease (AD), the most common form of
dementia affecting elderly people over the age of 65 and the sixth leading cause of death in
the United States (Alzheimer's, 2015). A key pathological feature of AD is the aggregation
of the tau protein and its deposition within neurons in the form of neurofibrillary tangles
(NFTs). In the healthy brain, tau stabilizes microtubules and supports intracellular
transportation. If tau is hyperphosphorylated, its binding affinity for tubulin is lowered,
increasing the probability that tau will aggregate and form tangles. The aberrant
phosphorylation of tau compromises microtubule stability, axonal transport and, therefore,
cognitive function (Gendron and Petrucelli, 2009).
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Patients that develop AD prior to age 65 are considered to have Early Onset AD and may
exhibit hereditable mutations in the Amyloid Precursor Protein (APP), Presenilin1 (PSEN1)
or Presenilin2 (PSEN2) genes (Liddell et al., 2001). Most individuals that develop AD
(>95%) have sporadic or Late Onset AD (LOAD) (Bekris et al., 2010). Genome analyses
have failed to identify a clear genetic etiology for this form of AD, suggesting the possibility
that environmental exposures and related epigenetic modifications play an important role in
the pathogenesis of sporadic forms of AD and other tauopathies (Karch and Goate, 2014;
Lunnon and Mill, 2013; Rosenthal and Kamboh, 2014).

Author Manuscript

The environment contains a number of toxicants that are risk factors for the development of
neurodegenerative diseases. These include, but are not limited to, pesticides (such as DDT),
metals, and air pollution (Dosunmu et al., 2007). The heavy metal lead (Pb) still poses a
danger as an environmental toxicant. While extant research does not provide clear evidence
that Pb exposure is the cause of AD or other tauopathies, the identification of relationships
between Pb poisoning and cognitive decline began to surface after several longitudinal and
cross-sectional studies were performed on the elderly. The Normative Aging Study, a
prospective continuing study started by the Veterans Administration in 1963, has shown that
participants with higher levels of Pb in the blood/bone exhibited diminished performance in
cognitive measures such as the Wechsler Adult Intelligence Scale-Revised and Mini-Mental
state examination (Payton et al.,1998; Weisskopf et al., 2007, 2004; Wright et al., 2003).
In conjunction with this data collected in humans, recent research has demonstrated that
mice exposed to Pb postnatally performed worse during cognitive behavior tests as aged
adults (Bihaqi and Zawia, 2013). These behavioral deficits correlated with the changes in the
protein and gene expression levels of tau, phosphorylated tau, related enzymes and
Neurotoxicology. Author manuscript; available in PMC 2017 December 21.
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transcription factors (Bihaqi et al., 2014; Bihaqi and Zawia, 2013). More recently we
discovered that epigenetic mediators such as microRNA may paly a role in mediating these
changes in gene expression (Masoud et al., 2016). Developmental Pb studies completed in
the wild-type mice were replicated in non-human primates. Results from the primate study
were consistent with those found in the mouse model. Furthermore, the exposed primates
showed a development of NFTs at the end of life, a classic pathological marker of AD
(Bihaqi and Zawia, 2013).

Author Manuscript

To translate the results seen in our rodent and primate studies into a human application, we
have implemented the use of a transgenic mouse model that possesses the gene for human
tau. Prior studies have provided strong evidence for the ability of an environmental toxin to
affect the murine tau gene, but there is a critical need to examine the relationship between
toxins and the human tau gene because the mouse and human genes produce different
protein products. The mouse gene does not produce all of the isoforms produced by the
human gene. This whole line of investigation would have to come to a dead end if it was
discovered that the human gene was not sensitive to the effects of Pb exposure.
The present study utilizes a transgenic mouse that has a homozygous knock-out of the
murine tau gene and is hemizygous for the human tau gene. On a molecular level, this
transgene includes the promoter, intronic regions, and regulatory regions of the human
MAPT gene. The transgenic mouse model develops all six isoforms of the human protein
tau, including both 3R and 4R isoforms. Since the adult mouse brain contains exclusively
the 4R tau isoform, while the adult human brain contains roughly equal amounts of 3R and
4R, this model has a representative human tau ratio (Andorfer et al., 2003).
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The primary purpose of the current research was to explore the utility of this transgenic
mouse model in the study of interactions between environmental toxicants and the human
tau gene. Our investigation examined whether the human tau transgene is responsive to
exposure to a developmental toxicant by determining the effect of this exposure on tau
protein and gene expression. In addition, we surveyed the impact of the toxicant on a
population of miRNA that target the mRNA for MAPT.

2. Methodology
2.1. Animals and exposure

Author Manuscript

This study employed the transgenic mouse model B6.Cg-Mapttm1(GFP)Klt
Tg(MAPT)8cPdav/J [Jackson Laboratory Stock 005491, Bar Harbor, ME]). No endogenous
mouse MAPT is detected in these mice, but all six isoforms (including both 3R and 4R
forms) of human MAPT are expressed. Mice were bred in the Animal Care Facility at the
University of Rhode Island (Kingston, RI). All experiments were performed in accordance
with the standard guidelines and protocol approved by the University of Rhode Island
Institutional Animal Care and Use Committee (IACUC) with supervision of the university's
veterinarian.
The transgenic mice were divided into two groups. One group of mice was exposed to Pb
during the first 20 days of postnatal life according to the protocol we have published
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previously (Bihaqi et al., 2014). Mice in the second cohort were not exposed to Pb and
served as controls. The first group was exposed to 0.2% Pb Acetate via the drinking water of
their respective dams. Lead acetate (500 mg) was dissolved in 250 mL of deionized water.
This exposure protocol causes the concentration of Pb in the cerebellum of PND 20 rodents
(0.25+/- 0.07 μg/g) to be approximately three times the level seen in control animals (Zawia
and Harry, 1996). Blood levels have been shown to be 46.43 (μg/dl during Pb exposure but
are reduced to basal levels in adults (Basha et al., 2005). Exposure began 24 h after birth
(PND 1) and continued until weaning (PND 20). Mice were euthanized with CO2 at PND
20, PND 30, PND 40 and PND 60 for protein and mRNA measures and at PND 20 and PN
D50 for miRNA assays. For each time point and exposure group there was an n = 3. The
brains were removed and placed on ice followed by immediate storage at −80°C.
2.2. Genotyping

Author Manuscript

Pups born in-house were weaned, separated by sex, and genotyped at PND 20. Tail snips of
2 mm were taken from each mouse and a DNA extraction was performed on each sample.
The resulting DNA was amplified with the following primers— transgene sense: 5′CGAAGTGATGGAAGATCACG-3′ and transgene antisense: 5′GTCTTGGTGCATGGTGTAGC-3′. Amplification was conducted under the following
conditions: 94 °C for 2min followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s and 72 °C
for 1 min. The amplified product was electrophoresed on a 2% agarose gel at 100 V for 90
min and imaged on the Amersham Typhoon Imager Scanner FLA 9000 (GE Life Sciences,
Piscataway, NJ).
2.3. Protein levels

Author Manuscript

Western blots were utilized to examine protein levels of total tau, phosphorylated tau
Ser396, and cyclin dependent kinase 5 (CDK5). The following protocol was used to prepare
samples for total tau, Ser396, and CDK5: 50 mg of cerebral cortical brain tissue was
homogenized in 1 mL of radioimmunoprecipitation assay (RIPA) lysis buffer containing 10
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1
mM ethylenediaminetetraacetic acid and 2 μL protease inhibitor, and 10 μL phosphatase
inhibitor. The homogenates were placed on ice for 10min before being centrifuged at 8000×
RPM for 10 min at 4°C. Lysate protein concentrations were determined by a bicinchoninic
acid assay (Thermo Scientific Pierce, Rockford, IL), at 560 nm using the Spectra-Max
Multimode plate reader (Molecular Devices, Sunnyvale, CA). Following protein
standardization, samples were prepared for western blotting according to the concentrations
listed in Table 1.

Author Manuscript

Samples were separated on polyacrylamide gels at 85 V for 90min and then transferred to
PVDF membranes (Millipore, Billerica, MA). Membranes were blocked at room
temperature and incubated overnight with blocking buffer and primary antibody (Table 1)
with gentle shaking at 4°C. The membranes were then washed with TBST three times and
incubated with the appropriate secondary antibody. The membranes were washed 3 times
with TBST and 3 times with TBS. Membranes were imaged on the Odyssey® Infrared
Imaging System (Li-Cor, Lincoln, NE). All blots were normalized to housekeeping proteins
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GAPDH or β-Actin. Total tau and phospho-tau blots were normalized to GAPDH. CDK5
was normalized to β-Actin.
2.4. Immunohistochemistry

Author Manuscript

Immunohistochemistry was used to visually confirm the presence of hyperphosphorylated
tau in 13-month-old mice. While our study involved developmental profiles, we used older
mice to confirm the presence of tau immunoreactvity and to observe for pathological
deposits associated with the presence of the human tau gene. These normally do not fully
manifest until an older age. According to a protocol previously published (Subaiea et al.,
2015), mice were deeply anesthetized with an intraperitoneal injection of 0.1 ml/10 g of
xylazine-ketamine mixture (100-10 mg/ml) and were perfused transcardially with 100 ml of
perfusion wash containing 0.8% sodium chloride, 0.8% sucrose, 0.4% dextrose, 0.034%
anhydrous sodium cacodylate, and 0.023% calcium chloride. Mice were then perfused with
100 mL of perfusion fix containing 4% paraformaldehyde, 4% sucrose, and 1.07%
anhydrous sodium cacodylate, and their brains were removed. The extracted brains were
post-fixed in the perfusion fix solution overnight and then cryopreserved in 30% sucrose
solution at −20 °C. Fixed brains were sent to NeuroScience Associates (Knoxville, TN) and
stained with 1:2500 phospho-tau Thr181 (Thermo Scientific Pierce, Rockford, IL).
2.5. RNA and micro RNA (miRNA) isolation and real-time PCR

Author Manuscript

Total RNA was isolated from Pb-exposed and non-exposed cerebral cortex tissue according
to the TRIzol method (Invitrogen, Carlsbad, CA). Purity and concentration were confirmed
using a Nanodrop UV/vis Spectrophotometer (Thermo Scientific, Wilmington, DE). First
strand complementary DNA (cDNA) was synthesized from 1 (μg total RNA using the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA) for mRNA and NCode™ VILO™ miRNA
cDNA Synthesis Kit (Invitrogen, CA) for miRNA. cDNA was amplified using real-time
polymerase chain reaction (PCR). The SYBR Green quantitative real-time PCR assay was
performed in 12.5 μl (20 μl for miRNA) reactions using 1 μl cDNA template, 1 X SYBR
Green master mix (Applied Biosystems, Foster City, CA), 0.5 μM forward and reverse
primers, and deionized H2O. The primers utilized can be found in Table 2. Amplification
was performed on ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA)
following the standard protocol: 50°C for 2min followed by 95 °C for 10min, then 40 cycles
of 95 °C for 15 s and 60 °C for 1 min. Results were analyzed with with ViiA 7, and
expression was reported relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA with the 2−ΔΔCT method for mRNA and 2−ΔCT for miRNA which was normalized to
small nucleolar RNA 202 (sno202).
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2.6. Statistical analysis
Western blot bands were quantified using the Li-Cor Odyssey infrared image system. Real
time PCR curves were quantified using Viia7 Real-Time PCR System software. All
measurements were made in triplicate and all values are presented as mean istandard error of
the mean. Analyzing the protein and mRNA levels of the Pb-exposed group versus the
control groups tested the responsiveness of the transgene to Pb exposure. One-way analysis
of variance (ANOVA) for each gene was performed with the Newman-Keuls multiplecomparison post hoc test. Newman-Keuls was chosen as the preferred method for a stepwise
Neurotoxicology. Author manuscript; available in PMC 2017 December 21.
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approach to pairwise comparisons of the mean responses due to increased power among
smaller number of treatment groups. To determine the significance of interaction between
Pb-exposure and the time points investigated, a two-way ANOVA and a Newman-Keuls
multiple-comparison post hoc test was performed for each gene's protein expression. Effect
sizes were calculated to assess the magnitude of the interaction between Pb-exposure and
time. The level of significance for each ANOVA was set at α= 0.05. All analyses were
performed using Sigma Stat 3.5 computer software.

3. Results
3.1. Genotyping and immunohistochemical characterization of the human tau phenotype

Author Manuscript

Genotyping and immunohistochemistry were conducted on aged sibilings of the
experimental cohorts as part of the model validation. Analysis of DNA obtained from the
tails of PND20 mice revealed clear differences between mice carrying the transgene versus
non-carrier controls. Immunohistochemical staining for phosphorylated tau (Thr181) in
older (13 month) transgene carriers demonstrated clear evidence of hyperphosphorylation in
multiple cerebral cortical regions, including the internal capsule (Supplementary Fig. 1A)
and the external capsule (Supplementary Fig. 1B).
3.2. Effect of Pb exposure on biomarkers of neurodegeneration

Author Manuscript

Protein levels of cerebral cortical total tau normalized to GAPDH were analyzed by Western
blot after postnatal dosing with 0.2% Pb acetate for 20days (Fig. 1A). One-way ANOVA
revealed a dramatic increase in total tau protein levels in the brains of Pb-exposed mice at
PND 20 and 30 which then returned to basal levels by PND 40-60 (p=0.008, p=0.006
respectively) (Fig. 1B). A two-way ANOVA revealed a statistically significant interaction
between the time points and Pb-exposure (p=<0.001). The interaction effect, η2, for this
relationship is 0.512 revealing that 51 % of the variance was due to an interaction between
time and exposure. Tau mRNA was evaluated for Pb's ability to affect expression. Analysis
of tau mRNA levels shows that at PND 20, postnatal Pb exposure has a similar up-regulation
effect on the expression of tau at the transcriptional level (Fig. 1C).

Author Manuscript

The cerebral cortical levels of phosphorylated tau Ser396 normalized to GAPDH were
analyzed by Western blot after postnatal lead exposure (Fig. 2A). Results from a one-way
ANOVA revealed a significant increase of phosphorylated protein expression in Pb-exposed
mice at PND 20 and PND30, which also normalized at PND40-60 (p=0.001 and p=0.001,
respectively) (Fig. 2B). Two-way ANOVA findings revealed a statistically significant
interaction between the time points and exposure (p < 0.001). The h2 for this interaction is
0.510 revealing that 51% of the variance is attributed to the interaction between exposure
and time.
Cerebral cortical CDK5 normalized to β-actin was analyzed by Western blot to measure the
effect of Pb on the kinase's protein expression levels (Fig. 3A). CDK5 levels in Pb-exposed
mice showed an up-regulation trend at every time point as compared to controls (Fig. 3B).
At PND 40 and PND 60, a one-way ANOVA test reported a significant difference (p = 0.001
and p< 0.001, respectively). A two-way ANOVA revealed that the effect of Pb exposure does
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not depend on the time point. Stated differently, there is no statistically significant
interaction between the time points and exposure (p = 0.067). η2 for this interaction is 0.127;
a finding that reveals just under 13% of the variance can be attributed to the interaction
effect between Pb exposure and time. CDK5 mRNA levels also followed a pattern of
consistent upregulation in the Pb-exposed mice compared to unexposed controls (Fig. 3C).
One-way ANOVA results revealed no statistical significance between the treatment groups
for CDK5 gene expression.
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Recent studies by us have suggested that microRNAs may play a role in mediating Pbinduced changes in gene expression. We have shown previously that exposing wild-type
mice to Pb produces a transient increase in the expression of miRNA that target APP mRNA
and the mRNA for proteins involved in promoter methylation (Masoud et al., 2016). This
increase in the expression of select miRNA coincided with a period of decreased protein
expression that followed the Pb exposure, suggesting that the miRNA might be inhibiting the
translation of these proteins. In the present study, we found that Pb exposure produced an
analogous and significant (p=0.037) increase in the expression of miR-34c between PND20
and PND50 (Fig. 4). This miRNA has been shown to target the mRNA for human MAPT
(Wu et al., 2013).

4. Discussion
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Extant findings for wild-type mice have provided evidence that developmental Pb exposure
has an effect on tau, its kinase's and phospho-tau (Bihaqi et al., 2014). The expressed
hypothesis of this study was focused on identifying the responsiveness of the human tau
transgene to an environmental exposure. Initial genotyping confirmed that transgenic mice
adequately express human tau and that murine endogenous tau was expectedly absent due to
its deletion. Immunohistochemical staining in aged mice with an antibody for phospho-tau
site Thr181 validates that the mouse model has high levels of phosphorylated tau in various
brain structures as they age. This is in accordance with previously published findings
(Andorfer et al., 2003).
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Western blotting and quantitative real time PCR demonstrated that Pb has an effect on the
human tau gene transcription and translation. Previous studies have shown postnatal
exposure in wild-type mice increases levels of tau, phosphorylated tau, and its related
enzymes (Bihaqi et al., 2014). We tested to see the same pattern within the transgenic mouse
model between PND 20-60. The findings from this current study illustrated that Pb indeed
has an effect on the human tau gene which occurs within a stage-specific developmental
window and then normalized by adulthood. These observations are consistent with
numerous studies reported by our group on the impact of developmental Pb exposure and
gene expression and more recently shown to occur for tau (Bihaqi et al., 2014). The latent
effects of elevated tau levels in late life seen in the wild-type mice are possibly being
established and further aging of these mice would be expected to reveal a delayed
upregulation in this biomarker in old age.
The phosphorylated tau serine 396 protein levels follow the same upregulation pattern of the
total tau protein levels (Figs.1–2). This infers that as more total tau is being translated,
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phosphorylation of the protein is also increasing; suggesting that the hyperphosphorylation
of tau is substrate driven. The total tau mRNA levels illustrate that the upregulation of
transcription at PND 20 results in excessive protein translation and subsequent
phosphorylation at PND 20 and 30. At PND 40 and PND 60 the transcriptional levels are
similar in pattern to the protein levels.
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Additional western blotting showed consistent elevated levels of CDK5 in Pb-exposed mice
compared to controls. This was analogous to the two-year Pb exposure study done in the
wild-type mouse model (Bihaqi et al., 2014); however, it is important to note that both
CDK5 levels and gene expression are belatedly elevated on PND 40 and such elevation is
sustained throughout their adulthood. This suggests that while CDK5 can contribute to the
posttranslational modification of tau, it is not responsive to substrate levels and may be
activated by alternate pathways. It is also important to note that Ser396 is a major target of
glycogen synthase kinase 3 (GSK3), a second kinase of tau (Kimura et al., 2014). CDK5
was the primary kinase evaluated in this study because of its importance in abnormal tau
phosphorylation as well as many GSK3 sites, including Ser396, needing to be primed by
CDK5 initially (Kimura et al., 2014).
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MicroRNAs (miRNA) are small non-coding RNA of ∼22 nucleotides that act as important
post-transcriptional regulators of gene expression by binding to the 3′ un-translated regions
of their target mRNAs, resulting in mRNA degradation or the inhibition of protein
translation (Goodall et al., 2013). It has been shown that miR-34c binds to human MAPT
mRNA and thus inhibits the expression of MAPT protein (Wu et al., 2013). In the present
study we demonstrate that early postnatal Pb exposure causes an increase in the expression
of this miRNA that coincides with the post-exposure normalization of tau expression that we
describe above. This data suggests that miRNA, including miR-34c, may play a critical role
in “correcting” the transient Pb-induced over-expression of tau, similar to the role suggested
for miRNA in the normalization of protein expression in wild-type mice exposed to Pb
(Masoud et al., 2016).
In summary, these studies demonstrate for the first time that exposure to an environmental
toxin can modulate a human gene and biomarkers associated with AD and tauopathies.
When compared with our previous work using wild-type animals, the present results indicate
that the human tau gene may in fact be more sensitive than the murine tau gene to
developmental Pb exposure. Future studies will explore the combined effects of the
environment and susceptible genes across the lifespan through old age. Furthermore,
epigenetic pathways that maybe associated with this genetic reprogramming will be
examined.
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Fig. 1.

Total tau expression in mice with postnatal exposure to Pb. (A) Changes in the
developmental profiles of tau protein expression in the cerebral cortex of control and
developmental exposure group (Pb). (B) Quantification of protein expression by
normalization to GAPDH. (C) Quantification of mRNA levels of total tau normalized to
GAPDH. Each data point in the bar diagram represents the mean ± SEMs (n = 3) for protein
and gene expression. **p < 0.010 as compared to unexposed controls. *p < 0.05 as
compared to unexposed controls and independently verified. Total tau protein and gene
expression was altered by postnatal Pb exposure.
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Fig. 2.
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Phospho-tau Ser396 expression in mice with postnatal exposure to Pb. (A) Changes in the
developmental profiles of phosphor-tau Ser396 protein expression in the cerebral cortex of
control and developmental exposure group (Pb). (B) Quantification of protein expression by
normalization to GAPDH. Each data point in the bar diagram represents the mean±SEMs (n
= 3) for protein expression. ***p < 0.001 as compared to unexposed controls. Phopho-tau
Ser936 protein expression was altered by postnatal Pb exposure.
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Fig. 3.

CDK5 expression in mice with postnatal exposure to Pb. (A) Changes in the developmental
profiles of CDK5 protein expression in the cerebral cortex of control and developmental
exposure group (Pb). (B) Quantification of protein expression by normalization to β-actin.
(C) Quantification of mRNA levels of CDK5 normalized to β-actin. Each data point in the
bar diagram represents the mean ± SEMs (n = 3) for protein and gene expression. ***p <
0.001 as compared to unexposed controls. CDK5 protein and gene expression was altered by
postnatal Pb exposure.
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Fig. 4.

Expression of miR-34c relative to sno202 in control animals (dotted line) and
Pbexposedanimals (PbE, solid line) at PND 20 and PND 50. Results expressed as mean ±
SEMs (n = 3 with measurements in triplicates). *p<0.05 as compared to unexposed controls.
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30min

30min

40min

20min in 5% BSA

20min in 5% BSA

1h in 5% BSA

1:500

1:1000

1:5000

Primary Antibody

1:1000 1h RT

40 μg

Ser396

10%

10%

Blocking

β-Actin

40 μg

CDK5

Transfer

1:1000 1h RT

10 μg

Tau

Gel

GAPDH

Protein

Gene
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Western blot protein concentrations and antibody ratios.

1:10,000 60min

1:10,000 60min

1:5,000 60min

1:10,000 60min

1:10,000 30min

Secondary Antibody
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Primer Sequences for qPCR.
Target

FORWARD PRIMER

REVERSE PRIMER

Tau

5′ -TGA ACC AGG ATG GCT GAG C-3′

5′-TTG TCA TCG CTT CCA GTC C-3′

CDK5

5′ -GGC TAA AAA CCG GGA AAC TC-3′

5′-CCA TTG CAG CTG TCG AAA TA-3′

SP1

5′ -TCA TAC CAG GTG CAA ACC AA-3′

5′-AGG TGA TGT TCC CAT TCA GG-3′

GAPDH

5′ -AGG TCG GTG TGA ACG GAT TTG-3′

5′-TGT AGA CCA TGT AGT TGA GGT CA-3′

miR-34c

[miRBase ID: MI0000403]: 5′-AGGCAGTGTAGTTAGCTGATTGC-3′

Universal primer provided with the kit

Sno202

5′ -GCTGTACTGACTTGATGAAG-3′

5′-CATCAGATGGAAAAGGGTTC-3′
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